Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...